Enclomiphene in women: does it actually work?

Last updated 2026-07-27

Is enclomiphene used in women at all?

Not in any standard or approved way. Enclomiphene is one of the two isomers that make up clomiphene citrate, the drug that's been used for ovulation induction since the FDA approved it in 1967 under the brand name Clomid ^[1]. Clomiphene citrate is roughly 62% enclomiphene (the trans isomer) and 38% zuclomiphene (the cis isomer) ^[2]. When people talk about "enclomiphene" as a product today, they almost always mean the isolated trans-isomer being developed and sold for men, to raise testosterone without shutting down sperm production. That men's use case is the entire reason enclomiphene exists as a separate compound in the current market. There is no FDA-approved enclomiphene product for women, and there's no significant body of current compounded-pharmacy practice built around it for female fertility either. If a clinic or website is offering you enclomiphene for ovulation induction as a female patient, that's off the well-trodden path, not a validated alternative to clomiphene. Some readers land here because they're partners of men using enclomiphene for TRT-alternative therapy and want to understand the fertility angle from the other side. If that's you, the short version: enclomiphene doesn't affect a female partner's cycle, hormones, or fertility. It only acts on the man taking it.

What's the difference between enclomiphene and clomiphene, really?

Clomiphene citrate is a mixture of two isomers, enclomiphene (trans) and zuclomiphene (cis), and they behave differently in the body. Enclomiphene is cleared relatively quickly, with a half life estimated around 10 hours, while zuclomiphene lingers, with a much longer half life, and some data suggest it can still be detected weeks after a dose ^[3]. That difference matters because zuclomiphene is thought to carry more of the estrogenic, side-effect-producing activity, including the mood changes and visual disturbances some women report on clomiphene. The idea behind isolating enclomiphene, going back to the Repros Therapeutics Androxal development program, was that the trans isomer does most of the useful anti-estrogenic work at the hypothalamus (blocking estrogen's negative feedback, which pushes LH and FSH up) without as much of the isomer baggage. In men, that translates to higher testosterone with less water retention and mood disruption than some experience on clomiphene. In women, the isomer-specific research never reached a marketed product; Androxal was studied exclusively as a male hypogonadism treatment and was never approved for anything ^[4]. So the practical distinction for a woman researching fertility drugs: clomiphene citrate is the approved, well-studied compound with a 50+ year track record in reproductive medicine. Enclomiphene alone is not that drug. It's a different molecule with a different, and thinner, evidence base, developed for a different patient population.

Was enclomiphene ever studied in women for ovulation or fertility?

There's some history here, but it's old and thin by modern standards. Enclomiphene (sometimes called zuclomiphene-depleted clomiphene in older literature) was studied in small trials in the 1980s and 1990s as an ovulation-induction agent, on the theory that removing the long-acting zuclomiphene isomer might reduce clomiphene's anti-estrogenic effects on the endometrium and cervical mucus, effects that can work against pregnancy even while they trigger ovulation. Those early studies were small, mostly single-center, and never led to a marketed female product. No enclomiphene-alone drug has gone through modern FDA Phase 3 trials for ovulation induction or any female indication. The regulatory and clinical energy over the last 15 years went entirely into the male hypogonadism program (Androxal), which itself stalled: Repros Therapeutics received a Complete Response Letter from the FDA in 2016, and the drug never reached approval or market for men either ^[5]. What this means practically: there is no current, adequately powered clinical trial data supporting enclomiphene for ovulation induction, PCOS-related infertility, or any female reproductive indication. Anyone offering it for that purpose is extrapolating from decades-old, small-sample research, not practicing evidence-based fertility medicine.

What does the FDA actually say about enclomiphene's approval status?

Enclomiphene has no FDA-approved product, for men or women. The Androxal New Drug Application from Repros Therapeutics was the closest anything got, and it did not clear the finish line. What's sold today as enclomiphene, for the male testosterone market, comes from compounding pharmacies operating under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which allow pharmacies to prepare drug products from bulk ingredients for individual patients or in anticipation of prescriptions, generally without the same premarket efficacy and safety review a new drug undergoes ^[6]. That's a meaningfully different regulatory footing than an FDA-approved drug like clomiphene citrate or letrozole. Compounded products aren't required to prove efficacy for a specific indication before reaching patients; oversight focuses more on the pharmacy's compounding practices and ingredient sourcing than on clinical trial data for the specific use. For men using enclomiphene on an off-label, compounded basis, that's a known and often-discussed tradeoff. For women, there isn't even an established off-label compounding pattern to point to, because the clinical rationale (isomer purity reducing endometrial effects) was never confirmed at scale.

If I want ovulation induction, what should I actually ask about?

Clomiphene citrate and letrozole are the two drugs with real trial weight behind them for ovulation induction, and either is a reasonable thing to bring up with a reproductive endocrinologist or OB-GYN. Letrozole, an aromatase inhibitor, has actually overtaken clomiphene as the first-line choice for women with PCOS-related anovulatory infertility in a lot of practices. The key NIH-funded trial (Legro et al., published in the New England Journal of Medicine in 2014) found live birth rates of 27.5% with letrozole versus 19.1% with clomiphene citrate among women with PCOS, a difference the authors called statistically significant ^[7]. That trial is a big part of why many reproductive endocrinologists now reach for letrozole first. Clomiphene citrate still has a long track record, an FDA-approved label for ovulation induction, and is generally cheaper and more widely stocked. Neither of these drugs is enclomiphene, and neither carries the isomer-purity marketing angle. But they're the ones with actual outcome data (ovulation rates, pregnancy rates, live birth rates) behind them. | Drug | FDA-approved for ovulation induction | Trial evidence in women | Typical use case |

Does enclomiphene affect a female partner if a man is using it for TRT?

No. Enclomiphene works at the level of the hypothalamus and pituitary in the person taking it, raising their own LH and FSH signaling and, in men, their own testicular testosterone and sperm production. It doesn't transfer meaningfully through casual contact, and there's no mechanism by which a male partner's enclomiphene use would alter a female partner's cycle, ovulation, or hormone levels. This question comes up a lot from couples where the man is using enclomiphene specifically because they're trying to conceive and want to avoid the fertility-suppressing effects of exogenous testosterone. That's actually the core clinical rationale for choosing enclomiphene over TRT in a man who still wants to father children: unlike injectable testosterone, which shuts down the hypothalamic-pituitary-gonadal axis and can suppress sperm counts to very low levels or zero, enclomiphene stimulates the same axis rather than replacing its output, which tends to preserve spermatogenesis and testicular size . That's a real and clinically meaningful distinction for the couple as a unit, even though the drug itself is only acting on the man. If you're the male partner navigating that decision, the practical dosing questions (how much, how often, how to actually administer it) are covered in our guides on Enclomiphene Direct dosage and the Enclomiphene Direct dosage calculator.

Are there any hormonal or off-label uses of enclomiphene being explored in women?

There's ongoing academic interest in SERMs generally for things outside classic ovulation induction, but nothing specific to enclomiphene alone has reached mainstream clinical use in women. Tamoxifen and raloxifene, other SERMs, are established drugs for breast cancer risk reduction and osteoporosis respectively, and that broader SERM class does get studied for various female hormonal applications. But that's a different molecule family conversation than isolated enclomiphene. Some fertility researchers have floated the idea that isomer-pure enclomiphene could theoretically avoid some of clomiphene's anti-estrogenic side effects on the endometrial lining and cervical mucus, effects that can work against the very pregnancy the drug is meant to help achieve. That's a reasonable scientific hypothesis. It has not been confirmed in a modern, adequately powered trial, and no pharmaceutical company currently has an active female-indication enclomiphene program moving through FDA trials as far as public records show. If you see a clinic marketing enclomiphene specifically to women for fertility, ask directly what trial data they're relying on and how recent it is. "Isomer-pure so it should work better" is a hypothesis, not a demonstrated outcome.

What should men on enclomiphene know if fertility preservation is the goal?

The mechanism is the whole reason to consider enclomiphene over standard TRT if maintaining fertility matters to you. Exogenous testosterone (injections, gels, pellets) tells the hypothalamus and pituitary that there's plenty of testosterone around already, so they cut back on GnRH, LH, and FSH signaling. Less LH and FSH means less stimulation of the testes, which means lower intratesticular testosterone (the concentration that actually matters for sperm production, which runs far higher than blood levels) and often reduced testicular size over months of use. Enclomiphene, by blocking estrogen receptors at the hypothalamus, does close to the opposite: it removes some of estrogen's negative feedback, so LH and FSH pulses increase, and the testes respond by producing more of their own testosterone alongside continued sperm production. That's the theoretical basis for why enclomiphene tends to preserve fertility and testicular volume in a way TRT doesn't, and small studies in hypogonadal men support the LH/FSH and testosterone effects, though large, modern RCTs on live birth or semen parameters specifically are still limited. None of this is a guarantee. Fertility preservation isn't the same as fertility improvement, and men with pre-existing sperm quality issues shouldn't assume enclomiphene will fix them. If fertility is a real near-term goal, get a baseline semen analysis before starting anything, work with a urologist or reproductive endocrinologist, and don't treat any hormone therapy, enclomiphene included, as a substitute for that kind of monitoring. Understanding proper administration matters too here; see our guides on how to reconstitute Enclomiphene Direct and Enclomiphene Direct how to inject if you're starting therapy and want to do it correctly.

Where does the compounded enclomiphene market actually stand today?

Compounded enclomiphene for men is a real, active corner of the men's health and TRT-alternative market, sold through telehealth clinics and compounding pharmacies operating under Section 503A or 503B of the FD&C Act ^[6]. It's typically dosed as capsules or, less commonly, an injectable/reconstituted format, usually in the 6.25mg to 25mg per day range depending on the protocol and the prescriber, though there's no single FDA-set dose because there's no FDA-approved product to set one. Because it's compounded rather than FDA-approved, quality and dosing accuracy depend heavily on which pharmacy is actually making it. That's a real consideration: 503A and 503B pharmacies operate under different oversight structures, and not all compounding pharmacies hold themselves to the same testing standards. If you're sourcing enclomiphene, working through a provider-reviewed pathway rather than an anonymous online seller matters, partly because a licensed prescriber should be checking baseline labs (total and free testosterone, LH, FSH, estradiol) before you start and rechecking at follow-up. Enclomiphene Direct works this way: prescriptions are provider-reviewed and fulfilled through a licensed pharmacy partner, rather than sold as an unreviewed over-the-counter product. None of that changes the female-use picture, though. The compounded market that exists is built for men on a testosterone-and-fertility protocol, not for women seeking ovulation induction. If you're a man figuring out how long a typical course runs, our page on Enclomiphene Direct cycle length and Enclomiphene Direct injection sites covers the practical side of that.

Bottom line: should a woman use enclomiphene?

Based on current evidence, no, not outside of a research setting with informed consent about how thin the data is. There's no FDA-approved enclomiphene product for women, no modern trial establishing efficacy or safety for ovulation induction, and no compounding-pharmacy consensus protocol built around it the way there is for men's testosterone therapy. Women dealing with anovulatory infertility, PCOS, or unexplained subfertility have two options with real trial weight behind them: clomiphene citrate, approved by the FDA since 1967 ^[1], and letrozole, which outperformed clomiphene on live birth rate in the 2014 NEJM PCOS trial ^[7]. Either is worth discussing with a reproductive endocrinologist. Isolated enclomiphene isn't currently one of the standard options, and "it's the purer isomer" isn't the same as "it's been shown to work."

Frequently asked questions

Can women take enclomiphene for fertility?

There's no FDA-approved enclomiphene product for women and no modern trial data supporting it for ovulation induction. Clomiphene citrate (which contains enclomiphene plus zuclomiphene) and letrozole are the established, evidence-backed options. Isolated enclomiphene alone hasn't been validated in current clinical trials for female fertility use.

What's the difference between enclomiphene and clomiphene?

Clomiphene citrate is a mix of two isomers, enclomiphene (trans) and zuclomiphene (cis). Enclomiphene clears the body faster (half-life around 10 hours) while zuclomiphene lingers much longer. Isolated enclomiphene is marketed for men wanting a testosterone boost with preserved fertility; clomiphene citrate, the mixture, is the approved drug used in women for ovulation induction.

Does enclomiphene affect a female partner's hormones or fertility?

No. Enclomiphene acts on the hypothalamus and pituitary of the person taking it, raising their own LH, FSH, and testosterone. It has no mechanism to affect a partner's cycle or hormones. It's not transferred through contact, and a female partner's fertility is unaffected by a man's enclomiphene use.

Is enclomiphene FDA-approved for anyone?

No. Enclomiphene was developed by Repros Therapeutics under the name Androxal for male hypogonadism, but the FDA issued a Complete Response Letter in 2016 and it never reached approval. What's sold today is compounded by pharmacies under Section 503A or 503B of the FD&C Act, not an FDA-approved drug product.

Why does enclomiphene preserve fertility while TRT doesn't?

TRT supplies external testosterone, which signals the brain to reduce LH and FSH, cutting testicular stimulation and often sperm production. Enclomiphene blocks estrogen feedback at the hypothalamus instead, increasing LH and FSH so the testes keep producing their own testosterone and sperm. That's the mechanistic reason it tends to preserve fertility and testicular size where TRT often doesn't.

What should a woman with PCOS or anovulatory infertility ask her doctor about instead?

Ask about clomiphene citrate and letrozole. A 2014 NEJM trial (Legro et al.) found letrozole produced a 27.5% live birth rate versus 19.1% for clomiphene in women with PCOS, which is why many reproductive endocrinologists now use letrozole first. Both have real trial data; enclomiphene alone currently does not.

Was enclomiphene ever studied in women historically?

Yes, in small trials during the 1980s-90s exploring whether removing the zuclomiphene isomer would reduce clomiphene's anti-estrogenic effects on the endometrium. Those trials were small and dated, never led to an approved female product, and haven't been repeated with modern trial standards, so the evidence base remains thin.

Can enclomiphene be compounded for women by a pharmacy?

Technically a compounding pharmacy could prepare it under Section 503A or 503B for an individual prescription, but there's no established clinical protocol, dosing standard, or efficacy data supporting that use in women. It would be an off-label, largely unstudied use, not a recognized fertility treatment pathway.

How is enclomiphene dosed for men, and does that apply to women?

Men typically use compounded enclomiphene in ranges around 6.25mg to 25mg daily, set by a prescriber since there's no FDA-approved dose. That dosing comes from male hypogonadism protocols and testosterone targets; it has no established equivalent or validated translation for female use, so it shouldn't be extrapolated for women.

Does taking clomiphene mean I'm taking enclomiphene?

Partly, yes. Clomiphene citrate is roughly 62% enclomiphene and 38% zuclomiphene by weight. If you've been prescribed clomiphene for ovulation induction, you are receiving enclomiphene, just combined with the zuclomiphene isomer rather than isolated alone.

Is letrozole better than clomiphene for PCOS-related infertility?

In the 2014 NEJM trial of women with PCOS, letrozole produced a higher live birth rate (27.5%) than clomiphene citrate (19.1%), a statistically significant difference. That evidence is a major reason many reproductive endocrinologists now recommend letrozole as first-line therapy for anovulatory PCOS patients, though clomiphene remains a valid, FDA-approved option.

If my partner is on enclomiphene and we're trying to conceive, does anything change for me?

No direct hormonal change happens to you. The relevant benefit is indirect: your partner may maintain more normal sperm production on enclomiphene than he would on standard TRT, which suppresses spermatogenesis. A baseline semen analysis for him, done before starting any hormone therapy, is the most useful step if conception is the near-term goal.

Sources

1. FDA, Clomid (clomiphene citrate) approval history: Clomiphene citrate has been FDA-approved for ovulation induction since 1967
2. PubMed, clomiphene citrate isomer composition: Clomiphene citrate is a mixture of approximately 62% enclomiphene and 38% zuclomiphene
3. PubMed, pharmacokinetics of clomiphene isomers: Enclomiphene and zuclomiphene have markedly different half-lives, with zuclomiphene persisting much longer
4. ClinicalTrials.gov, Androxal (enclomiphene citrate) program listing: Enclomiphene (Androxal) was developed and studied specifically for male secondary hypogonadism
5. Repros Therapeutics, SEC Form 8-K disclosure on FDA Complete Response Letter: The FDA issued a Complete Response Letter for Androxal (enclomiphene) in 2016 and the drug was not approved
6. New England Journal of Medicine, Legro et al. 2014, Letrozole vs Clomiphene for Infertility in the Polycystic Ovary Syndrome: Letrozole produced a 27.5% live birth rate versus 19.1% for clomiphene citrate in women with PCOS
7. Journal of Urology / American Urological Association, review of SERMs and male fertility preservation: Unlike exogenous testosterone, SERMs like enclomiphene stimulate endogenous LH/FSH and tend to preserve spermatogenesis and testicular volume